Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
NCT ID: NCT07185958
Last Updated: 2025-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
80 participants
OBSERVATIONAL
2025-09-22
2028-03-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of Circulating Biomarkers of Immunogenic Cell Death
NCT02921854
Pilot Investigation of Dual Energy CT Imaging on an Online Adaptive Radiation Therapy System
NCT07219134
Single-fraction IMRT Versus External Beam Radiotherapy for Patients With Spine Bone Metastases
NCT02358720
ReIrradiation with FDG-PET Guided Dose Painting
NCT02921581
Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)
NCT04135794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DART Brain (whole)
Patients with 1-5 brain metastases referred for whole brain radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent + extra MRI scan with Gadolinium-based contrast agent.
Dual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
Iodine-based contrast agent
Administered intravenously with DECT for enhanced imaging.
Magnetic Resonance Imaging (MRI)
Additional MRI scan performed for tumor and OAR delineation.
Gadolinium-based contrast agent
Administered intravenously with MRI for enhanced imaging.
DART Brain (SRS)
Patients with 1-5 brain metastases referred for stereotactic radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent.
Dual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
Iodine-based contrast agent
Administered intravenously with DECT for enhanced imaging.
DART Bone (pall)
Patients with bone metastases without medullary involvement in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum) referred for palliative radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent + extra MRI scan without contrast agent.
Dual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
Iodine-based contrast agent
Administered intravenously with DECT for enhanced imaging.
Magnetic Resonance Imaging (MRI)
Additional MRI scan performed for tumor and OAR delineation.
DART Bone (SBRT)
Patients with bone metastases without medullary involvement in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum) referred for palliative radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent.
Dual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
Iodine-based contrast agent
Administered intravenously with DECT for enhanced imaging.
DART H&N
Patients with head and neck cancer referred for radiotherapy. Patients must have undergone a PET/CT scan during the diagnostic evaluation for cancer. Intervention: Extra DECT scan without contrast agent.
Dual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
DART Lung
Patients with lung cancer referred for palliative radiotherapy with a maximum of 10 fractions. Interventions: Extra DECT scan in breath-hold without contrast agent.
Dual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
Iodine-based contrast agent
Administered intravenously with DECT for enhanced imaging.
Magnetic Resonance Imaging (MRI)
Additional MRI scan performed for tumor and OAR delineation.
Gadolinium-based contrast agent
Administered intravenously with MRI for enhanced imaging.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Assessed to be able to complete the protocol scanning regime
* Referred for RT
* For head and neck cancer patients, a PET/CT scan must have been performed during the diagnostic evaluation for cancer
* Signed informed consent
Exclusion Criteria
* Previous RT in the same anatomical area now referred for RT
* Previous surgery in the same anatomical area now referred for RT
* Participation in conflicting protocols
* If relevant for the protocol scanning regime: Allergic to contrast agent
* If relevant for the protocol scanning regime: Contraindication to iodine-based contrast agent for CT (as determined by the physician)
* If relevant for the protocol scanning regime: Contraindication to Gadolinium-based contrast agent for MRI (as determined by the physician)
* If relevant for the protocol scanning regime: Contraindication for MRI (pacemaker, metal, non-MRI, compatible implants etc.)
* Incapable of understanding the patient information
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Copenhagen University Hospital at Herlev
OTHER
Odense University Hospital
OTHER
Aalborg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hella Maria Brøgger Sand
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hella MB Sand, Medical Physicist, MSc
Role: PRINCIPAL_INVESTIGATOR
Department of Medical Physics, Oncology, Aalborg University Hospital, Aalborg, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalborg University Hospital
Aalborg, , Denmark
Copenhagen University Hospital Herlev and Gentofte
Herlev, , Denmark
Odense University Hospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-20250004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.